Acelyrin Q2 2024 GAAP EPS $(0.86) Misses $(0.69) Estimate
Portfolio Pulse from Benzinga Newsdesk
Acelyrin (NASDAQ:SLRN) reported a Q2 2024 GAAP EPS of $(0.86), missing the analyst consensus estimate of $(0.69) by 24.64%. This represents a 115% increase in losses compared to $(0.40) per share from the same period last year.
August 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acelyrin reported a Q2 2024 GAAP EPS of $(0.86), missing the analyst consensus estimate of $(0.69) by 24.64%. This represents a significant increase in losses compared to the same period last year.
The significant miss on earnings estimates and the substantial increase in losses compared to the previous year are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100